Showing results (141-150 of 158) with videos related to

Sort By:
Pageof 16
Neuro-Oncology|December 4, 2019
Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastomaChibawanye I Ene, Shannon A Kreuser, Miyeon Jung, et al.
Neuro-Oncology Advances|March 30, 2026
Comparison of clinical, radiographic and genomic alterations between histologic and molecular glioblastoma, <i>IDH</i>-wildtypeDaniel H Lachance, Paul A Decker, Thomas M Kollmeyer, et al.
The Lancet. Oncology|July 9, 2017
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trialPaul D Brown, Karla V Ballman, Jane H Cerhan, et al.
Molecular Cancer Research : MCR|February 22, 2022
Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL InhibitionMasum Rahman, Ian Olson, Moustafa Mansour, et al.
Cancer Immunology Research|March 15, 2023
Anti-PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I ExpressionZachariah P Tritz, Katayoun Ayasoufi, Delaney M Wolf, et al.
International Journal of Radiation Oncology, Biology, Physics|October 27, 2019
Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3)Daniel M Trifiletti, Karla V Ballman, Paul D Brown, et al.
Molecular Cancer Therapeutics|July 5, 2018
Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain BarrierMinjee Kim, Daniel J Ma, David Calligaris, et al.
JAMA Oncology|October 20, 2022
Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis: A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical TrialJoshua D Palmer, Brett G Klamer, Karla V Ballman, et al.
Nature Communications|January 12, 2024
Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trialEvanthia Galanis, Katharine E Dooley, S Keith Anderson, et al.
Medrxiv : the Preprint Server for Health Sciences|May 27, 2024
The dynamic impact of location and resection on the glioma CSF proteomeCecile Riviere-Cazaux, Christopher J Graser, Arthur E Warrington, et al.
Pageof 16